Skip to content
2000
Volume 28, Issue 13
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Tumor growth inhibition can be achieved by inhibiting angiogenesis, which has been a field of great concern in recent years. Important targets to inhibit angiogenesis include vascular endothelial growth factor receptor (VEGFR) and its homologous tyrosine kinase receptor. Anti-angiogenic therapy based on inhibition of VEGFR-2 is an effective clinical treatment strategy. The research progress of VEGFR-2 inhibitors is reviewed in this paper from the aspects of drug development and chemical synthesis.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867327666200514082425
2021-04-01
2025-05-07
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867327666200514082425
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test